A naukri.com initiative
Medium
4w
128
Image Credit: Medium
Nvax, waiting for better times
- Novavax Inc is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.
- Novavax has recently announced a licensing agreement with Sanofi to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines.
- Novavax AB is headquartered in Uppsala, Sweden and Novavax CZ is located in Bohumil, Czech Republic, both dedicated to vaccine manufacturing.
- Novavax uses proprietary technology to produce vaccine candidates, which are genetically engineered three-dimensional nanostructures that incorporate recombinant proteins critical to disease pathogenesis.
- Novavax's vaccine pipeline targets a variety of infectious diseases with clinical vaccine candidates for respiratory syncytial virus (RSV) and Ebola virus (EBOV).
- The company is also developing proprietary technology for the production of immune stimulating saponin-based adjuvants through its Swedish subsidiary, Novavax AB.
- In 2016, the company's Phase III trial of its RSV vaccine had failed to meet its endpoints, which caused its share price to fall and led the company to lay off 30% of its employees.
- Currently, analysts are estimating that Novavax, Inc. (NVAX) will hit a $3.70 price target and the median price target for the stock is set at $1.50.
- Shares of Novavax, Inc. (NASDAQ:NVAX) have come into focus as if the company can gain some positive momentum.
- Novavax is a biotechnology company that has recently gained attention due to its involvement in the production of COVID-19 vaccines.
Read Full Article
7 Likes
For uninterrupted reading, download the app